226 related articles for article (PubMed ID: 34404561)
1. Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Jomrich G; Kollmann D; Ramazanova D; Ristl R; Grose RP; Ilhan-Mutlu A; Preusser M; Fassnacht C; Tsai YC; Guenova E; Schoppmann SF
Eur J Surg Oncol; 2022 Feb; 48(2):383-390. PubMed ID: 34404561
[TBL] [Abstract][Full Text] [Related]
2. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer.
Hynes CF; Kwon DH; Vadlamudi C; Lofthus A; Iwamoto A; Chahine JJ; Desale S; Margolis M; Kallakury BV; Watson TJ; Haddad NG; Marshall MB
Ann Thorac Surg; 2018 Oct; 106(4):1002-1007. PubMed ID: 29859152
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
5. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
[TBL] [Abstract][Full Text] [Related]
6. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.
Dislich B; Stein A; Seiler CA; Kröll D; Berezowska S; Zlobec I; Galvan J; Slotta-Huspenina J; Walch A; Langer R
Cancer Immunol Immunother; 2017 Jun; 66(6):777-786. PubMed ID: 28289861
[TBL] [Abstract][Full Text] [Related]
8. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Lin EM; Gong J; Klempner SJ; Chao J
World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
10. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Liang Y; Yu M; Zhou C; Zhu X
Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
12. Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.
Guo L; Song P; Xue X; Guo C; Han L; Fang Q; Ying J; Gao S; Li W
J Immunother; 2019; 42(6):215-220. PubMed ID: 31145232
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Rojkó L; Reiniger L; Téglási V; Fábián K; Pipek O; Vágvölgyi A; Agócs L; Fillinger J; Kajdácsi Z; Tímár J; Döme B; Szállási Z; Moldvay J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1219-1226. PubMed ID: 29675791
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
